1 May 2011AmericasEric Steffe

Clinical trials in BioPharma

Biotechnology companies, however, are sometimes unprepared for the intellectual property considerations that arise as a promising drug (either their own or one licensed from a university) progresses through clinical trials. Eric Steffe explains.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

LSPN Fall: Gilead GC shares top drafting tips

PierFerd adds AI patent partner with ‘dynamic experience’

LSPN Fall: Why Big Pharma is facing 'a balancing act'

GSK fires pair of COVID and RSV lawsuits at Moderna

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

Novo Nordisk targets Canada’s largest generics maker over diabetes drug

Powell Gilbert co-founder moves to US firm

Roche to outside counsel: ‘Law firms must adapt to the modern world’

Clinical trials in BioPharma

Editor's picks

Editor's picks

More features